The EPS miss and lack of revenue reinforce the pre-revenue biotech risk. Monitor for upcoming ALX2004 safety data in 2H 2026 and ASPEN-09-Breast topline in mid-2027. The $169M cash runway through 1H 2028 provides a buffer but does not offset the fundamental miss.
Price Chart
Executive Summary
ALX Oncology reported Q1 2026 GAAP EPS of -$0.17, significantly missing the consensus estimate of -$0.16 (a -6.25% miss). The company had no revenue. While clinical data for evorpacept in HER2-positive breast cancer showed promising durable responses, the EPS miss and lack of near-term revenue catalysts weigh on the outlook.
Key Financial Metrics
Key Facts
- GAAP net loss per share of -$0.17 vs consensus -$0.16 (miss of 6.25%)
- No revenue reported for Q1 2026
- Cash, cash equivalents and investments of $169.1M as of March 31, 2026, sufficient through first half of 2028
- R&D expenses decreased to $13.6M from $23.9M year-over-year due to workforce reduction and pipeline prioritization
- Phase 2 ASPEN-09-Breast trial topline data expected mid-2027; Phase 1 ALX2004 safety data expected 2H 2026
- Completed $150M equity offering in February 2026, selling ~77M shares at $1.57/share plus pre-funded warrants
Financial Impact
EPS miss of $0.01 vs consensus; net loss of $17.9M for the quarter
Risk Factors
- Clinical trial failure or delay for evorpacept or ALX2004
- Dilution risk from February 2026 equity offering (77M shares issued)
- No near-term revenue or profitability catalysts
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291041 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 9d ago | SC 13D/A | $1.14 $1.13 | ▼ −0.88% | ▼ −0.73% | $1.13 (−0.88%) |
Oct 15, 2026 11d ago | 8-K | $1.06 $1.17 | ▲ +10.38% | ▲ +10.81% | $1.13 (+6.60%) |
Sep 28, 2026 28d ago | Press Release | $1.39 $1.21 | ▼ −12.95% | ▼ −14.15% | $1.13 (−18.71%) |
Aug 15, 2026 10w ago | Institutional Cluster | $1.97 $1.99 | ▲ +1.02% | ▲ +2.21% | $1.13 (−42.64%) |
Aug 6, 2026 11w ago | 8-K | $2.11 $1.94 | ▼ −8.06% | ▼ −9.27% | $1.13 (−46.45%) |
Jun 30, 2026 16w ago | 8-K | $2.06 $2.36 | ▲ +14.56% | ▲ +14.30% | $1.13 (−45.15%) |
Jun 26, 2026 17w ago | 8-K | $2.20 $2.19 | ▼ −0.45% | ▼ −1.84% | $1.13 (−48.64%) |
Jun 12, 2026 19w ago | Institutional Cluster | $1.58 $1.53 | ▲ +3.16% | ▲ +3.84% | $1.13 (+28.48%) |
May 8, 2026 24w ago | 8-K | $2.08 $2.04 | ▼ −1.92% | ▼ −3.39% | $1.13 (−45.67%) |
May 8, 2026 24w ago | Press Release | $2.08 $2.04 | ▲ +1.92% | ▲ +3.39% | $1.13 (+45.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers